Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia 2019 (ICALL) /
Integrating, balancing and disregarding risk factors in paediatric acute lymphoblastic leukaemia

17th - 19th May 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.05.19
Views: 948
Rating:

Prof Anthony Moorman - Newcastle University, Newcastle, UK

Prof Anthony Moorman talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the integration of risk factors to precisely predict outcomes in paediatric acute lymphoblastic leukaemia (ALL).

He discusses the effectiveness of the minimal residual disease assessment both in isolation or in combination with other risk factors and how patients are currently assessed in the clinic.

Prof Moorman explains the possible role of personalised medicine according to tumour type and how these findings may apply to adults with ALL over the next few years.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation